SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

EQRx, Inc. EQRX NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

EQRx, Inc. (EQRX) is a Biotechnology company in the Healthcare sector, currently trading at $2.34. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Analyst consensus target is EQRX = $5 (+113.7% upside).

Net income is $205M, growing at -326177.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $4M against $1.4B equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 27.51 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $1.5B.

Analyst outlook: 1 / 4 analysts rate EQRX as buy (25%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 67/100 (Partial), Moat 40/100 (Fail), Future 52/100 (Partial), Income ?/100 (Fail).

$5.00

▲ 113.68% Upside

Average Price Target

The 12-month price target for EQRx, Inc. is $5.00.

EQRX SharesGrow Score Overview

50/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 25/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 40/100

Gross margin is + market cap

FUTURE 52/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — EQRX

EQRX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $5, implying +113.7% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

EQRX: +0%/yr revenue is, -326177.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

EQRX: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet EQRX: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 27.51 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

EQRX: Gross margin is 0% (+0 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 4 analysts rate EQRX as buy (25%). Analyst consensus target is $5 (+113.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range1.58-4.75

Volume11.93M

Avg Volume (30D)2.95M

Market Cap$1.14B

Beta (1Y)0.63

Share Statistics

EPS (TTM)0.43

Shares Outstanding$474.3M

IPO Date2021-06-03

Employees362

CEOMelanie I. Nallicheri

Financial Highlights & Ratios

EBITDA$-355.88M

Net Income$205.49M

Operating Income$-355.88M

Total Cash$1.4B

Total Debt$3.83M

Net Debt$-490.31M

Total Assets$1.46B

Price / Earnings (P/E)5.4

Analyst Forecast

1Y Price Target$5.00

Target High$5.00

Target Low$5.00

Upside+113.7%

Rating ConsensusHold

Analysts Covering4

Buy 25% Hold 50% Sell 25%

Company Info

CountryUS

ExchangeNASDAQ Global Market

CurrencyUSD

ISINUS26886C1071

Price Chart

EQRX

EQRx, Inc. ↗ · NASDAQ Global Market

Healthcare • Biotechnology

1.58 52WK RANGE 4.75

People Also View

Revolution Medicines, Inc.

Blueprint Medicines Corporation

Kymera Therapeutics, Inc.

Edgewise Therapeutics, Inc.

Relay Therapeutics, Inc.

Stoke Therapeutics, Inc.

Mineralys Therapeutics, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message